calcipotriol/betamethasone dipropionate / Generic mfg. - LARVOL DELTA

Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Al-Azhar University

New trial • Dermatology • Immunology • Psoriasis

Breaking therapeutic barriers: rapid efficacy of calcipotriol/betamethasone cream (Wynzora®) in psoriasis patients unwilling to initiate systemic therapy (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Real‑World Effectiveness of Calcipotriol/Betamethasone Dipropionate Cream (Wynzora®) in Mild‑to‑Moderate Psoriasis: A Four‑Patient Case Series (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis

Real-world evaluation of calcipotriol/betamethasone dipropionate PAD-cream (Wynzora®) in chronic plaque psoriasis across two UK dermatology centres (EADV 2026) - No abstract available

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Rapid and Effective Management of Psoriasis in Difficult-to-Treat Areas Using Calcipotriol/Betamethasone PAD-Cream: A Four-Case Series (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Topical Betamethasone/Calcipotriol creme as an Effective Add‑On Therapy for Residual Psoriasis Plaques: Two Clinical Cases (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

MANAGING PSORIASIS IN THE ONCOLOGIC SETTING: THE ROLE OF TOPICAL CALCIPOTRIOL/BETAMETHASONE (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis

Paradoxical Psoriasis During Biologic Therapy: Successful Management with Calcipotriol/Betamethasone Cream (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis

Effects of calcipotriene/betamethasone dipropionate foam combined with phototherapy in an imiquimod-induced mouse model of psoriasis (EADV 2026) - No abstract available

Preclinical • Dermatology • Immunology • Psoriasis

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion. (PubMed, Ital J Dermatol Venerol) - "Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed."

Journal • Dermatology • Immunology • Psoriasis

Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study. (PubMed, Dermatol Ther (Heidelb)) - P | "High adherence to CAL/BDP PAD-cream was associated with greater effectiveness, satisfaction, preference, and QoL. While patients with low adherence still benefited, maximizing adherence is key for optimal real-world outcomes in scalp psoriasis."

Journal • Dermatology • Immunology • Psoriasis

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. (PubMed, Cureus) - "We further narrowed our focus to studies that could be aggregated into the intervention categories: phototherapy and systemic combination therapy (n=10), topical and topical combination therapy (n=15), and systemic monotherapy (n=5).  Treated versus control subjects showed statistically improved VASI after the following interventions were added to phototherapy: oral psoralen, oral minipulsed prednisone, implanted afamelanotide, topical ethyl vanillate, topical bimatoprost, and oral vitamins A and E. Effective topical therapies were ruxolitinib, calcipotriol and betamethasone, tacrolimus and mometasone, and microdermabrasion and tacrolimus. None of the systemic monotherapies was superior to their corresponding comparator."

Journal • Review • Aesthetic Medicine • Dermatology • Immunology • Vitiligo

Therapeutic outcomes of CAL/BDP PAD-based cream in patients with mild-to-moderate psoriasis: insights from four case reports. (PubMed, Drugs Context) - "CAL/BDP PAD-based cream appears promising for managing psoriasis in specific contexts such as lesions in difficult-to-treat areas or residual disease during biologic therapy. Further real-world data and clinical observations will be important to clarify how this formulation can be integrated into individualized management strategies for mild-to-moderate psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials. (PubMed, Dermatol Ther (Heidelb)) - "CAL/BDP PAD-cream was associated with significantly higher early response rates at W4 than CAL/BDP gel, suggesting earlier clinical improvements."

Journal • P3 data • Retrospective data • Dermatology • Immunology • Psoriasis

Systemic signs of rheumatoid activity. (BAD 2026) - "He had a history of seropositive rheumatoid arthritis (RA), which had been treated successfully with etanercept, although he had recently developed secondary failure...He had been treated by his general practitioner for a presumed psoriasis with calcipotriol– betamethasone...Such signs can present despite biologic treatment, and indicate a high burden of disease activity. The identification of these signs is important as adjustment of medication can often lead to resolution of symptoms and improved control of joint disease."

Dermatitis • Immunology • Inflammatory Arthritis • Psoriasis • Rheumatoid Arthritis • Vasculitis

The long-term efficacy of managing and discharging patients from direct-to-patient teledermatology for inflammatory dermatoses (BAD 2026) - "Management recommendations included topical steroid (n = 30, 23%), calcipotriol/betamethasone (n = 10, 8%) and other topical i64 Abstracts preparations (n = 17, 13%)...DTPT reduces demand on outpatient clinics, administrative burden on general practitioners, and unnecessary patient travel, while affording dermatologists flexible and remote work. As the demand on primary care and dermatology increases, DTPT could become a highly effective way to streamline patient pathways."

Clinical • Atopic Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Psoriasis • Rosacea

Retrospective real world evaluation of Wynzora cream efficacy and safety (BAD 2026) - "Fixeddose calcipotriol–betamethasone dipropionate (CAL/BDP) combinations are recommended first line due to once-daily dosing and favourable safety. High patient satisfaction was driven by the nongreasy, easy-to-apply formulation, with particular benefit reported for scaling and scalp involvement. Wynzora cream demonstrates meaningful real-world efficacy, safety and acceptability, supporting its role as both primary and adjunctive topical therapy in routine clinical practice."

HEOR • Real-world • Real-world evidence • Retrospective data • Immunology • Inflammation • Plaque Psoriasis • Psoriasis

Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift. (PubMed, Front Immunol) - "A 13-year-old female patient with ACH showed poor responses to systemic acitretin, upadacitinib, and topical calcipotriol/betamethasone. After switching to systemic Xeligekimab, her hand and foot pustules improved rapidly, but eczematous eruptions appeared...The Palmoplantar Pustulosis Area and Severity Index (PPPASI), Dermatology Life Quality Index (DLQI), and Nail Psoriasis Severity Index (NAPSI) all decreased substantially, and no immune drift recurred. This case suggests that local injection of an IL-17 inhibitor may effectively control skin lesions while potentially avoiding systemic immune imbalance, offering a preliminary novel treatment approach for refractory ACH that requires further validation."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A

Intravital Monitoring of Psoriasis Treatment Response and Drug Delivery Using Multiphoton Fluorescence Lifetime Imaging. (PubMed, Skin Res Technol) - "MPT-FLIM proved to be a suitable tool for monitoring treatment response in psoriasis patients and tracking drug delivery. It could be a potential method for monitoring other inflammatory skin diseases during treatment to adjust therapy on an individual level."

Journal • Dermatology • Immunology • Inflammation • Oncology • Psoriasis

Perception and Satisfaction with Calcipotriol and Betamethasone Dipropionate PAD-Cream in Patients with Plaque Psoriasis: Results From a Survey. (PubMed, Dermatol Pract Concept) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

Paradoxical Immune Reactions under IL-17 Blockade: Insights from a Clinical Case Series (EADV-Sp 2026) - "Topical treatment with mometasone furoate ointment and keratolytic agents was initiated...Case 2: A 50-year-old female patient with a history of psoriatic arthritis (PsA) since 2021 and PV since 2022 was switched to ixekizumab in December 2022 after methotrexate (MTX) and apremilast proved ineffective...Topical treatment with calcipotriol and betamethasone dipropionate foam was prescribed, leading to a favorable clinical response...However, worsening of PV prompted a switch to adalimumab in August 2023, followed by a further switch to risankizumab in October 2024 due to fluctuating disease activity. Case 4: A 56-year-old woman with palmoplantar PV and autoimmune thyroiditis was started on ixekizumab in November 2025 after failure of MTX and topical therapies (betamethasone+calcipotriol and tazarotene)...Ixekizumab was discontinued, and treatment with topical steroids and systemic colchicine was initiated, resulting in marked improvement within two months...Conclusions..."

Clinical • Endocrine Disorders • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Seronegative Spondyloarthropathies

Nivolumab-induced lichen planus masquerading as a psoriatic flare (EADV-Sp 2026) - "With a history of psoriasis, the eruption was initially managed as a presumed flare with emollients and topical calcipotriol–betamethasone...Potent topical corticosteroids and doxycycline were commenced, achieving control without interrupting nivolumab...In the era of onco-dermatology, accurate recognition of subtle morphologic clues is essential. Careful clinicopathologic correlation not only guides appropriate treatment but also preserves vital oncologic options and optimises patient quality of life."

Colorectal Cancer • Dermatology • Dermatopathology • Immunology • Lichen Planus • Psoriasis • Solid Tumor

Calcipotriol/betamethasone cream for scalp psoriasis treatment: insights from a prospective Study. (EADV-Sp 2026) - "Notably, 51.5% of patients were treatment-naïve (no prior therapy for scalp psoriasis). Conclusions Once-daily Cal/BDP cream achieved rapid and clinically meaningful improvements in extent, objective severity, and pruritus in scalp psoriasis, including high rates of near-complete or complete clearance, supporting its effectiveness in this traditionally difficult-to-treat area."

Clinical • Dermatology • Immunology • Pruritus • Psoriasis

Erythrokeratoderma Variabilis With Persistent Facial Involvement, An Affected Sibling And Secondary Dermatophyte Infection (EADV-Sp 2026) - "The patient was treated with topical luliconazole for dermatophyte infection and systemic acitretin (25 mg/day) with topical calcipotriol/betamethasone for EKV, and was placed under regular clinical follow-up. Secondary dermatophyte infection may obscure the underlying genodermatosis and complicate diagnosis. Integrated clinical, histopathological and mycological assessment enables accurate diagnosis and appropriate combined antifungal and systemic therapy in EKV."

Infectious Disease

Challenges in recognizing and treating plaque psoriasis in a darker skin phototype (EADV-Sp 2026) - "Because of this incomplete response, after two months, therapy was switched to subcutaneous methotrexate 15 mg weekly together with calcipotriol/betamethasone as local therapy. Acitretin, through its effects on keratinocyte proliferation and differentiation, and regulation of inflammation, remains an effective systemic option and should be considered within an individualized treatment strategy, particularly when long- term safety and non-immunosuppressive therapy are priorities. Moreover, in darker skin phototypes, the effect of acitretin on the suppressing of keratinocyte hyperproliferation and inflammation, not only leads to disease remission, but also enables fading of post-inflammatory hyperpigmentation, which results in a more uniform skin tone over time."

Dermatology • Immunology • Infectious Disease • Inflammation • Plaque Psoriasis • Psoriasis • Respiratory Diseases • Tuberculosis